A decade ago, only a small group of vascular specialists believed that endovascular exclusion would become a feasible alternative treatment for abdominal aortic aneurysms (AAA). Even fewer had considered creating fenestrated graft technology to treat occlusive and aneurysmal disease involving significant arterial branches. Each of these concepts has now progressed from bench-top to clinical application through investigations conducted worldwide. The literature is presenting intermediate-term results of studies using commercially prepared bifurcated aortic endoprostheses, bringing to the fore both positive and, as one could have anticipated, disappointing-even unexpected-consequences of these increasingly popular procedures.
The Editors of the Journal are pleased to present this group of reports on the development of graft implantation techniques to assure preservation of branch flow during the endoluminal correction of complex AAA disease. So important is this new information that we have expedited publication of these exciting works, 2 of which were submitted from Australia within weeks of each other. Dr. Michael Lawrence-Brown, a pioneer in aortic endografting, and his colleagues in Perth have pursued the concept of fenestration for several years. first case of renal artery fenestration of an aortic endograft at the International Endovascular Symposium '98 in Sydney 3 and has since been adding to his experience, now at 13 patients in his latest report. 4 Last and by no means least is Dr. Tim Chuter's elaboration on the Australian concepts. 5 His technique for a multifenestrated device incorporated 6 side branch arteries in a procedure that must have been an imaging tour de force, not to mention a challenge for any interventionist's catheter skills.
If there is one word that encapsulates the work presented in this symposium, it is customization. The recent US Food and Drug Administration release of 2 ''off the shelf'' endografts (Medtronic's AneuRx and Guidant's Ancure) may have created the notion that these devices are similar to the classical grafts used in aortic resection and replacement, but nothing could be further from the truth. As the results based on broader use of both these prostheses become available, it will be apparent that the endoluminal process to exclude AAAs is not simple but complex. Advancing the techniques to juxtarenal and suprarenal geography requires extensive preprocedural assessment, exacting measurements, and customized fabrication of the devices, as evidenced by these authors' works. This in itself will create, at least for the present, a hindrance to usage in most institutions. In the case of the Australians, for example, these groups have in common Dr. David Hartley, who has been instrumental in the preparation of their fenestrated endografts. These initial results and the ingenuity and handicraft of the grafts deserve merit and respect by all interventionists.
Examining the Australian reports, the similarities are readily apparent. The devices are modifications of the Zenith stent-graft that is designed for suprarenal fixation with the aid of barbed struts on the uncovered proximal stent. They incorporate fenestrations into the body of the graft to accommodate cannulation of the branch artery ostium. Each group uses Palmaz stents to stabilize the graft-renal ostium junction and fix the fenestrations in place. Both agree that two thirds of the stent should be in the renal artery and one third in the endograft lumen. One notable difference, however, is that Dr. Anderson's group modifies the Palmaz stents by flaring the aortic end so that the struts are tacked back flush with the graft. This provides ready access to the renal vessel in the future and may add needed security to the fenestration fixation. The Perth group had not adopted this flaring modification in their reported cases, and 1 endograft migrated after a year, creating a type I endoleak when the fenestration was dislodged.
How well these side branch preservation techniques perform in larger clinical experiences will be a focal point of aortic endograft research in 2001. Just as important, however, will be their evolutionary path toward easyto-use devices that have broader clinical utility. We are excited by the prospects these works hold and their potential to expand the application of endovascular aortic aneurysm repair.
